These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12583451)

  • 21. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E; Hogg RS; Lima VD; Kerr T; Yip B; Marshall BD; Montaner JS
    JAMA; 2008 Aug; 300(5):550-4. PubMed ID: 18677027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.
    Palella FJ; Baker RK; Buchacz K; Chmiel JS; Tedaldi EM; Novak RM; Durham MD; Brooks JT;
    AIDS; 2011 Sep; 25(15):1865-76. PubMed ID: 21811144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
    MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
    HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort.
    Breaux K; Gadde S; Graviss EA; Rodriguez-Barradas MC
    AIDS Care; 2010 Jul; 22(7):886-94. PubMed ID: 20635253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
    Dheda K; Lampe FC; Johnson MA; Lipman MC
    J Infect Dis; 2004 Nov; 190(9):1670-6. PubMed ID: 15478074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence.
    Verweel G; Saavedra-Lozano J; van Rossum AM; Ramilo O; de Groot R
    Pediatr Infect Dis J; 2006 Nov; 25(11):987-94. PubMed ID: 17072119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era.
    Vincent B; Timsit JF; Auburtin M; Schortgen F; Bouadma L; Wolff M; Regnier B
    Intensive Care Med; 2004 May; 30(5):859-66. PubMed ID: 14767592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Survival analysis of HIV/AIDS patients with access to highly antiretroviral therapy in Ningbo during 2004-2015].
    Zhang JH; Li HL; Shi HB; Jiang HB; Hong H; Dong HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Sep; 37(9):1262-1267. PubMed ID: 27655575
    [No Abstract]   [Full Text] [Related]  

  • 38. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.